Ichor Medical Systems Awarded Key Electroporation Patent
SAN DIEGO, August 24, 2005 - Ichor Medical Systems, Inc. today announced that it has been issued a patent that protects vital elements of the company’s technology. U.S. Patent Number 6,912,417 entitled, “Method and Apparatus for Delivery of Therapeutic Agents,” is the first patent to issue from a family of applications that discloses a means to enable the commercialization of human therapies delivered by electroporation.
Electroporation uses the propagation of electric fields to greatly increase the uptake of DNA drugs by cells. Although this technique has been widely used in research laboratories, the development of clinical products based on this technology has been hindered by the lack of a simple, reliable, and effective means for procedure administration. Ichor’s TriGrid™ Delivery System integrates several patented technologies, including that disclosed in Patent Number 6,912,417, into a simple handheld device that is designed to enable safe, efficient, and reproducible DNA drug delivery with minimal operator training. Previous patents issued to Ichor cover the means for inducing the electroporation effect at specific treatment sites.
“This patent provides Ichor with broad coverage of an invention that provides the basis for transforming electroporation from an interesting research tool to a practical and commercially viable drug delivery technology,” said Drew Hannaman, Vice President – Research and Development of Ichor Medical Systems. “Our TriGrid™ Delivery System allows consistent, reproducible results to be achieved with a simple administration process. That important advantage is derived from proprietary technology covered by our portfolio of patents.”
Ichor Medical Systems, Inc. is a private company developing products based on the in vivo application of electroporation. Ichor’s proprietary TriGrid™ Delivery System uses electrical fields to dramatically increase DNA drug delivery efficiency. This approach employs a device-based system to enhance the delivery of virtually any DNA vaccine or therapeutic protein. By enabling the effective administration of this class of drugs, the company is leveraging the substantial investments made by others in the DNA drug sector to develop high-margin integrated products. The company’s initial development efforts are focused on the integration of the TriGrid™ Delivery System with existing DNA drug candidates for which initial safety and efficacy have been characterized. These drug candidates target cancer, autoimmune diseases and infectious diseases.
For additional information, call (858) 550-2022 or visit www.ichorms.com.